Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., has made two appointments to expand its Alzheimer’s disease business with renowned experts in the neuroscience field. Dr. Harald Hampel joins the company as vice president, Global Medical Affairs and Dr. Michael Irizarry was named vice president, Clinical Research. Both executives will work on advancing the company’s pipeline of Alzheimer’s disease and dementia compounds.   “The additions of Dr. Hampel a...